RBC Capital Reiterates Sector Perform on Darden Restaurants (DRI) Following 1Q Report
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Oppenheimer Reiterates Outperform on Darden Restaurants (DRI) Following 1Q Report
October 5, 2016 9:51 AM EDTOppenheimer reiterated an Outperform rating and $70.00 price target on Darden Restaurants (NYSE: DRI) following the company's 1Q earnings report. DRI reported EPS of $0.88, ahead of the Street's $0.82 estimate. Management raised F17E EPS guidance to $3.87-$3.97 (was $3.80-$3.90), vs. Street's $3.87.
Analyst Brian Bittner... More
Options with increasing volume: MTDR BRCD VNO
October 4, 2016 9:47 AM EDTOptions with increasing volume: MTDR BRCD VNO DRI BRCD NEM DAL NFLX HPE SDRL ETSY AAL NBR DOV BLDP TGP MUX
... MorePre-Open Stock Movers 10/04: (SMMT) (SDRL) (ARLZ) Higher; (TRIB) (IRMD) (TWTR) Lower (more...)
October 4, 2016 9:22 AM EDTToday's Pre-Open Stock Movers
Summit Therapeutics plc (Nasdaq: SMMT) 80% HIGHER; Sarepta Therapeutics (Nasdaq: SRPT) and Summit Therapeutics plc (Nasdaq: SMMT) announced that they have entered into an exclusive license and collaboration agreement granting Sarepta rights in Europe, as well as in Turkey and the Commonwealth of Independent States (the licensed territory), to Summits utrophin modulator pipeline, including its lead clinical candidate, ezutromid, for the treatment of Duchenne muscular dystrophy (DMD). As part of the agreement, Sarepta also obtains an option... More
Darden Restaurants (DRI) Tops Q1 EPS by 6c; Boosts FY17 EPS Outlook; $500M Stock Buyback Approved
October 4, 2016 7:06 AM EDTDarden Restaurants (NYSE: DRI) reported Q1 EPS of $0.88, $0.06 better than the analyst estimate of $0.82. Revenue for the quarter came in at $1.71 billion versus the consensus estimate of $1.72 billion.
Same-restaurant sales increased 1.3% for the quarter.
Stock Buyback News:
During the... More
